EGFR and non-small cell lung carcinoma: Recently, INSIGHT2 trial showed that tepotinib plus osimertinib has a promising activity and acceptable safety in EGFR-mutated NSCLC patients with MET amplification as a mechanism of resistance to first-line osimertinib (Wu et al., 2024).